Browse 1,513 myasthenia gravis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Myasthenia gravis causes muscle weakness that gets worse with use and improves with rest, often starting with a drooping eyelid or double vision. For decades treatment relied mainly on steroids and broad immune suppression, with side effects that can be hard to live with. In recent years several new targeted medicines have been approved that act directly on the antibodies behind the disease.
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
for
Myasthenia Gravis,
Location: Morgantown WV
Sponsor: argenx
Sex: Female
Age: 0+
Code: NCT06299748
Recruiting
Physical Activity Monitoring in Myasthenia Gravis
for
Myasthenia Gravis
Location: Boston MA
Sponsor: Massachusetts General Hospital
Sex: All
Age: 18 - 70+
Code: NCT06277830
Recruiting
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
for
Childhood-onset Systemic Lupus Erythematous,
Location: Washington D.C. DC, Cincinnati OH, St Louis MO
Sponsor: Cartesian Therapeutics
Sex: All
Age: 12+
Code: NCT07089121
Phase 1, Phase 2, Recruiting
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
for
Myasthenia Gravis
Location: Philadelphia PA, Hershey PA, Tampa FL, Ann Arbor MI,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 2 - 17
Code: NCT05265273
Phase 2, Phase 3, Recruiting
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
for
Generalized Myasthenia Gravis, gMG
Location: Norfolk VA, Washington D.C. DC
Sponsor: Alexion Pharmaceuticals, Inc.
Sex: All
Age: 6 - 17
Code: NCT06607627
Phase 3, Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Location: Boston MA, Durham NC, Chapel Hill NC, Miami FL,
Sponsor: argenx
Sex: All
Age: 18+
Code: NCT07294170
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod